Okabena Investment Services Inc. Has $1.06 Million Position in Johnson & Johnson $JNJ

Okabena Investment Services Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 58.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 5,102 shares of the company’s stock after selling 7,121 shares during the period. Okabena Investment Services Inc.’s holdings in Johnson & Johnson were worth $1,056,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after acquiring an additional 3,731,074 shares during the period. State Street Corp grew its holdings in Johnson & Johnson by 1.3% during the 4th quarter. State Street Corp now owns 133,869,843 shares of the company’s stock worth $27,704,364,000 after acquiring an additional 1,663,782 shares during the period. Geode Capital Management LLC grew its holdings in Johnson & Johnson by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock worth $11,967,947,000 after acquiring an additional 1,738,292 shares during the period. Norges Bank acquired a new stake in Johnson & Johnson during the 4th quarter worth $6,924,523,000. Finally, Wellington Management Group LLP grew its holdings in Johnson & Johnson by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock worth $4,789,914,000 after acquiring an additional 956,239 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Bank of America boosted their price target on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Barclays boosted their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Finally, Johnson Rice raised shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a report on Wednesday, May 13th. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $253.04.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced a more than $1 billion investment in Jacksonville, Florida to expand Vision manufacturing, packaging, and distribution. The move supports its U.S. expansion strategy and could improve long-term supply resilience and growth in its eye-care business. Article Title
• Positive Sentiment: J&J is also seeing renewed optimism around its pipeline after reporting strong Phase 2/3 results for IMAAVY (nipocalimab) in a rare autoimmune anemia and receiving FDA Priority Review, which could support future revenue growth if approved. Article Title
• Neutral Sentiment: Recent commentary suggests J&J’s shares have already had a strong multi-month run, so some investors are now debating whether the stock still offers value after a sharp one-year advance. Article Title
• Neutral Sentiment: J&J’s dividend increase and ongoing manufacturing push reinforce its defensive, income-oriented profile, but these items are more supportive of long-term sentiment than immediate share-price upside. Article Title

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $236.06 on Tuesday. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The firm has a market capitalization of $568.25 billion, a price-to-earnings ratio of 27.29, a price-to-earnings-growth ratio of 2.36 and a beta of 0.26. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The firm has a fifty day moving average of $231.37 and a 200-day moving average of $227.56.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the previous year, the business earned $2.77 EPS. The firm’s revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is presently 61.97%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.